>
  info@marketresearchfuture.com   đź“ž  +1 (855) 661-4441(US)   đź“ž  +44 1720 412 167(UK)
Certified Global Research Member
Isomar fd.webp Wcrc 57.webp
Key Questions Answered
  • Global Market Outlook
  • In-depth analysis of global and regional trends
  • Analyze and identify the major players in the market, their market share, key developments, etc.
  • To understand the capability of the major players based on products offered, financials, and strategies.
  • Identify disrupting products, companies, and trends.
  • To identify opportunities in the market.
  • Analyze the key challenges in the market.
  • Analyze the regional penetration of players, products, and services in the market.
  • Comparison of major players’ financial performance.
  • Evaluate strategies adopted by major players.
  • Recommendations
Why Choose Market Research Future?
  • Vigorous research methodologies for specific market.
  • Knowledge partners across the globe
  • Large network of partner consultants.
  • Ever-increasing/ Escalating data base with quarterly monitoring of various markets
  • Trusted by fortune 500 companies/startups/ universities/organizations
  • Large database of 5000+ markets reports.
  • Effective and prompt pre- and post-sales support.

Heart Tumor Market Research Report Information by Tumor Type (Primary Tumors and Secondary Tumors), by Diagnosis & Treatment (Diagnosis & Treatment), by Region (North America, Europe, Asia-Pacific, and Rest of the World) - Forecast till 2032


ID: MRFR/HC/3629-CR | 137 Pages | Author: Kinjoll Dey| September 2022
Leading companies partner with us for data-driven Insights
client_1 client_2 client_3 client_4 client_5 client_6 client_7 client_8 client_9 client_10
Please fill in Business Email for Quick Response

TABLE OF CONTENTS

1 EXECUTIVE SUMMARY

1.1 OVERVIEW

2 MARKET INTRODUCTION

2.1 DEFINITION

2.2 SCOPE OF THE STUDY

2.3 RESEARCH OBJECTIVE

2.4 LIST OF ASSUMPTIONS

3 RESEARCH METHODOLOGY

3.1 OVERVIEW

3.2 DATA MINING

3.3 SECONDARY RESEARCH

3.4 PRIMARY RESEARCH

3.4.1 PRIMARY INTERVIEWS AND INFORMATION GATHERING PROCESS

3.4.2 BREAKDOWN OF PRIMARY RESPONDENTS

3.5 FORECASTING TECHNIQUES

3.6 RESEARCH METHODOLOGY FOR MARKET SIZE ESTIMATION

3.6.1 BOTTOM-UP APPROACH

3.6.2 TOP-DOWN APPROACH

3.7 DATA TRIANGULATION

3.8 VALIDATION

4 MARKET DYNAMICS

4.1 OVERVIEW

4.2 DRIVERS

4.2.1 GROWING PREVALENCE OF CARDIAC TUMORS

4.2.2 INCREASING NUMBER OF CANCER RESEARCH AND FUNDING

4.2.3 RISING NUMBER OF STRATEGIC INITIATIVES

4.3 RESTRAINTS

4.3.1 LACK OF AWARENESS AMONG PEOPLE

4.3.2 LACK OF SKILLED RADIOLOGISTS

4.4 OPPORTUNITIES

4.4.1 INCREASING INITIATIVES BY PUBLIC AND PRIVATE ORGANIZATIONS TO DRIVE AWARENESS REGARDING HEART TUMOR

5 MARKET FACTOR ANALYSIS

5.1 VALUE CHAIN ANALYSIS

5.1.1 R&D

5.1.2 MANUFACTURING

5.1.3 DISTRIBUTION & SALES

5.1.4 POST-SALES MONITORING

5.2 PORTER'S FIVE FORCES MODEL

5.2.1 THREAT OF NEW ENTRANTS

5.2.2 BARGAINING POWER OF SUPPLIERS

5.2.3 THREAT OF SUBSTITUTES

5.2.4 BARGAINING POWER OF BUYERS

5.2.5 INTENSITY OF RIVALRY

5.3 IMPACT OF COVID-19 ON THE HEART TUMOR MARKET

5.3.1 IMPACT ON SUPPLY CHAIN

5.3.2 IMPACT ON PRODUCTION

5.3.3 IMPACT ON KEY PLAYERS

5.3.4 IMPACT ON REGION

6 GLOBAL HEART TUMOR MARKET, TUMOR TYPE

6.1 OVERVIEW

6.2 PRIMARY TUMOR

6.3 SECONDARY TUMOR

7 GLOBAL HEART TUMOR MARKET, BY DIAGNOSIS & TREATMENT

7.1 OVERVIEW

7.2 DIAGNOSIS

7.2.1 CT SCAN

7.2.2 MRI SCAN

7.2.3 NUCLEAR IMAGING

7.2.4 ECHOCARDIOGRAPHY

7.2.5 OTHERS

7.3 TREATMENT

7.3.1 COST PER PROCEDURE

7.3.2 SURGERY

7.3.3 CHEMOTHERAPY

7.3.4 RADIOTHERAPY

7.3.5 OTHERS

8 GLOBAL HEART TUMOR MARKET, BY REGION

8.1 OVERVIEW

8.2 NORTH AMERICA

8.2.1 US

8.2.2 CANADA

8.3 EUROPE

8.3.1 GERMANY

8.3.2 UK

8.3.3 FRANCE

8.3.4 ITALY

8.3.5 SPAIN

8.3.6 REST OF EUROPE

8.4 ASIA-PACIFIC

8.4.1 JAPAN

8.4.2 CHINA

8.4.3 INDIA

8.4.4 AUSTRALIA

8.4.5 SOUTH KOREA

8.4.6 REST OF ASIA-PACIFIC

8.5 REST OF THE WORLD

8.5.1 MIDDLE EAST

8.5.2 AFRICA

8.5.3 LATIN AMERICA

9 COMPETITIVE LANDSCAPE

9.1 OVERVIEW

9.2 COMPETITIVE BENCHMARKING

9.3 MAJOR GROWTH STRATEGY IN THE GLOBAL HEART TUMOR MARKET

9.4 THE LEADING PLAYER IN TERMS OF THE NUMBER OF DEVELOPMENTS IN THE GLOBAL HEART TUMOR MARKET

9.5 KEY DEVELOPMENT ANALYSIS

9.6 KEY DEVELOPMENTS & GROWTH STRATEGIES

9.6.1 PRODUCT LAUNCH/ PRODUCT APPROVAL

9.6.2 PARTERSHIP/AGREEMENT

9.6.3 MERGER /ACQUISTION

9.6.4 EXPANSION /INVESTMENT

9.7 FINANCIAL MATRIX

9.7.1 SALES (USD MILLION), 2021

9.7.2 R&D EXPENDITURE (USD MILLION), 2021

10 COMPANY PROFILE

10.1 KONINKLIJKE PHILIPS N.V.

10.1.1 COMPANY OVERVIEW

10.1.2 FINANCIAL OVERVIEW

10.1.3 PRODUCTS/SERVICES OFFERED

10.1.4 KEY DEVELOPMENTS

10.1.5 SWOT ANALYSIS

10.1.6 KEY STRATEGIES

10.2 FUJIFILM CORPORATION

10.2.1 COMPANY OVERVIEW

10.2.2 FINANCIAL OVERVIEW

10.2.3 PRODUCTS OFFERED

10.2.4 KEY DEVELOPMENTS

10.2.5 SWOT ANALYSIS

10.2.6 KEY STRATEGIES

10.3 GE HEALTHCARE

10.3.1 COMPANY OVERVIEW

10.3.2 FINANCIAL OVERVIEW

10.3.3 PRODUCTS OFFERED

10.3.4 KEY DEVELOPMENTS

10.3.5 SWOT ANALYSIS

10.3.6 KEY STRATEGIES

10.4 SIEMENS

10.4.1 COMPANY OVERVIEW

10.4.2 FINANCIAL OVERVIEW

10.4.3 PRODUCTS OFFERED

10.4.4 KEY DEVELOPMENTS

10.4.5 KEY STRATEGIES

10.5 AMNEAL PHARMACEUTICALS LLC

10.5.1 COMPANY OVERVIEW

10.5.2 FINANCIAL OVERVIEW

10.5.3 PRODUCTS OFFERED

10.5.4 KEY DEVELOPMENTS

10.5.5 KEY STRATEGIES

10.6 SHIMADZU CORPORATION

10.6.1 COMPANY OVERVIEW

10.6.2 FINANCIAL OVERVIEW

10.6.3 PRODUCTS OFFERED

10.6.4 KEY DEVELOPMENTS

10.6.5 SWOT ANALYSIS

10.6.6 KEY STRATEGIES

10.7 TOMTEC IMAGING SYSTEMS GMBH

10.7.1 COMPANY OVERVIEW

10.7.2 FINANCIAL OVERVIEW

10.7.3 PRODUCTS OFFERED

10.7.4 KEY DEVELOPMENTS

10.7.5 KEY STRATEGIES

10.8 TOSHIBA CORPORATION

10.8.1 COMPANY OVERVIEWS

10.8.2 FINANCIAL OVERVIEW

10.8.3 PRODUCTS TOSHIBA CORPORATION OFFERED

10.8.4 KEY DEVELOPMENTS

10.8.5 SWOT ANALYSIS

10.8.6 KEY STRATEGIES

10.9 BOSTON SCIENTIFIC CORPORATION

10.9.1 COMPANY OVERVIEW

10.9.2 FINANCIAL OVERVIEW

10.9.3 PRODUCTS OFFERED

10.9.4 KEY DEVELOPMENTS

10.9.5 KEY STRATEGIES

10.10 TERUMO CARDIOVASCULAR SYSTEMS CORPORATION

10.10.1 COMPANY OVERVIEW

10.10.2 FINANCIAL OVERVIEW

10.10.3 PRODUCTS OFFERED

10.10.4 KEY DEVELOPMENTS

10.10.5 KEY STRATEGIES

11 APPENDIX

11.1 REFERENCES

11.2 RELATED REPORTS

LIST OF TABLES

TABLE 1 LIST OF ASSUMPTIONS & LIMITATIONS

TABLE 2 GLOBAL: HEART TUMOR MARKET, BY TUMOR TYPE, 2022-2030 (USD MILLION)

TABLE 3 GLOBAL: HEART TUMOR MARKET, BY TUMOR TYPE, 2022-2030 (CYCLES)

TABLE 4 GLOBAL: HEART TUMOR MARKET, FOR PRIMARY TUMOR, BY REGION, 2022-2030 (USD MILLION)

TABLE 5 GLOBAL: HEART TUMOR MARKET, FOR PRIMARY TUMOR, BY REGION, 2022-2030 (CYCLES)

TABLE 6 GLOBAL: HEART TUMOR MARKET, FOR SECONDARY TUMOR, BY REGION, 2022-2030 (USD MILLION)

TABLE 7 GLOBAL: HEART TUMOR MARKET, FOR SECONDARY TUMOR, BY REGION, 2022-2030 (CYCLES)

TABLE 8 GLOBAL: HEART TUMOR MARKET, BY DIAGNOSIS & TREATMENT, 2022-2030 (USD MILLION)

TABLE 9 GLOBAL: HEART TUMOR MARKET, FOR DIAGNOSIS, BY REGION, 2022-2030 (USD MILLION)

TABLE 10 GLOBAL: HEART TUMOR MARKET, FOR DIAGNOSIS, BY TYPE, 2022-2030 (USD MILLION)

TABLE 11 GLOBAL: HEART TUMOR MARKET, FOR CT SCAN, BY REGION, 2022-2030 (USD MILLION)

TABLE 12 GLOBAL: HEART TUMOR MARKET, FOR MRI SCAN, BY REGION, 2022-2030 (USD MILLION)

TABLE 13 GLOBAL: HEART TUMOR MARKET, FOR NUCLEAR IMAGING, BY REGION, 2022-2030 (USD MILLION)

TABLE 14 GLOBAL: HEART TUMOR MARKET, FOR ECHOCARDIOGRAPHY, BY REGION, 2022-2030 (USD MILLION)

TABLE 15 GLOBAL: HEART TUMOR MARKET, FOR OTHERS, BY REGION, 2022-2030 (USD MILLION)

TABLE 16 GLOBAL AVERAGE SELLING PRICE (ASP) FOR HEART TUMOR TREATMENT (USD)

TABLE 17 GLOBAL: HEART TUMOR MARKET, FOR TREATMENT, BY REGION, 2022-2030 (USD MILLION)

TABLE 18 GLOBAL: HEART TUMOR MARKET, FOR TREATMENT, BY TYPE, 2022-2030 (USD MILLION)

TABLE 19 GLOBAL: HEART TUMOR MARKET, FOR TREATMENT, BY TYPE, 2022-2030 (CYCLES)

TABLE 20 GLOBAL: HEART TUMOR MARKET, FOR SURGERY, BY REGION, 2022-2030 (USD MILLION)

TABLE 21 GLOBAL: HEART TUMOR MARKET, FOR SURGERY, BY REGION, 2022-2030 (CYCLES)

TABLE 22 GLOBAL: HEART TUMOR MARKET, FOR CHEMOTHERAPY, BY REGION, 2022-2030 (USD MILLION)

TABLE 23 GLOBAL: HEART TUMOR MARKET, FOR CHEMOTHERAPY, BY REGION, 2022-2030 (CYCLES)

TABLE 24 GLOBAL: HEART TUMOR MARKET, FOR RADIOTHERAPY, BY REGION, 2022-2030 (USD MILLION)

TABLE 25 GLOBAL: HEART TUMOR MARKET, FOR RADIOTHERAPY, BY REGION, 2022-2030 (CYCLES)

TABLE 26 GLOBAL: HEART TUMOR MARKET, FOR OTHERS, BY REGION, 2022-2030 (USD MILLION)

TABLE 27 GLOBAL: HEART TUMOR MARKET, FOR OTHERS, BY REGION, 2022-2030 (CYCLES)

TABLE 28 GLOBAL HEART TUMOR MARKET, BY REGION, 2022-2030 (USD MILLION)

TABLE 29 GLOBAL HEART TUMOR MARKET, BY REGION, 2022-2030 (CYCLES)

TABLE 30 NORTH AMERICA: HEART TUMOR MARKET, BY COUNTRY, 2022-2030 (USD MILLION)

TABLE 31 NORTH AMERICA: HEART TUMOR MARKET, BY COUNTRY, 2022-2030 (CYCLES)

TABLE 32 NORTH AMERICA: HEART TUMOR MARKET, BY TUMOR TYPE, 2022-2030 (USD MILLION)

TABLE 33 NORTH AMERICA: HEART TUMOR MARKET, BY TUMOR TYPE, 2022-2030 (CYCLES)

TABLE 34 NORTH AMERICA: HEART TUMOR MARKET, BY DIAGNOSIS & TREATMENT, 2022-2030 (USD MILLION)

TABLE 35 NORTH AMERICA: HEART TUMOR MARKET, BY DIAGNOSIS, 2022-2030 (USD MILLION)

TABLE 36 NORTH AMERICA: HEART TUMOR MARKET, BY TREATMENT, 2022-2030 (USD MILLION)

TABLE 37 NORTH AMERICA: HEART TUMOR MARKET, BY TREATMENT, 2022-2030 (CYCLES)

TABLE 38 US: HEART TUMOR MARKET, BY TUMOR TYPE, 2022-2030 (USD MILLION)

TABLE 39 US: HEART TUMOR MARKET, BY TUMOR TYPE, 2022-2030 (CYCLES)

TABLE 40 US: HEART TUMOR MARKET, BY DIAGNOSIS & TREATMENT, 2022-2030 (USD MILLION)

TABLE 41 US: HEART TUMOR MARKET, BY DIAGNOSIS, 2022-2030 (USD MILLION)

TABLE 42 US: HEART TUMOR MARKET, BY TREATMENT, 2022-2030 (USD MILLION)

TABLE 43 US: HEART TUMOR MARKET, BY TREATMENT, 2022-2030 (CYCLES)

TABLE 44 CANADA: HEART TUMOR MARKET, BY TUMOR TYPE, 2022-2030 (USD MILLION)

TABLE 45 CANADA: HEART TUMOR MARKET, BY TUMOR TYPE, 2022-2030 (CYCLES)

TABLE 46 CANADA: HEART TUMOR MARKET, BY DIAGNOSIS & TREATMENT, 2022-2030 (USD MILLION)

TABLE 47 CANADA: HEART TUMOR MARKET, BY DIAGNOSIS, 2022-2030 (USD MILLION)

TABLE 48 CANADA: HEART TUMOR MARKET, BY TREATMENT, 2022-2030 (USD MILLION)

TABLE 49 CANADA: HEART TUMOR MARKET, BY TREATMENT, 2022-2030 (CYCLES)

TABLE 50 EUROPE: HEART TUMOR MARKET, BY COUNTRY, 2022-2030 (USD MILLION)

TABLE 51 EUROPE: HEART TUMOR MARKET, BY COUNTRY, 2022-2030 (CYCLES)

TABLE 52 EUROPE: HEART TUMOR MARKET, BY TUMOR TYPE, 2022-2030 (USD MILLION)

TABLE 53 EUROPE: HEART TUMOR MARKET, BY TUMOR TYPE, 2022-2030 (CYCLES)

TABLE 54 EUROPE: HEART TUMOR MARKET, BY DIAGNOSIS & TREATMENT, 2022-2030 (USD MILLION)

TABLE 55 EUROPE: HEART TUMOR MARKET, BY DIAGNOSIS, 2022-2030 (USD MILLION)

TABLE 56 EUROPE: HEART TUMOR MARKET, BY TREATMENT, 2022-2030 (USD MILLION)

TABLE 57 EUROPE: HEART TUMOR MARKET, BY TREATMENT, 2022-2030 (CYCLES)

TABLE 58 GERMANY: HEART TUMOR MARKET, BY TUMOR TYPE, 2022-2030 (USD MILLION)

TABLE 59 GERMANY: HEART TUMOR MARKET, BY TUMOR TYPE, 2022-2030 (CYCLES)

TABLE 60 GERMANY: HEART TUMOR MARKET, BY DIAGNOSIS & TREATMENT, 2022-2030 (USD MILLION)

TABLE 61 GERMANY: HEART TUMOR MARKET, BY DIAGNOSIS, 2022-2030 (USD MILLION)

TABLE 62 GERMANY: HEART TUMOR MARKET, BY TREATMENT, 2022-2030 (USD MILLION)

TABLE 63 GERMANY: HEART TUMOR MARKET, BY TREATMENT, 2022-2030 (CYCLES)

TABLE 64 UK: HEART TUMOR MARKET, BY TUMOR TYPE, 2022-2030 (USD MILLION)

TABLE 65 UK: HEART TUMOR MARKET, BY TUMOR TYPE, 2022-2030 (CYCLES)

TABLE 66 UK: HEART TUMOR MARKET, BY DIAGNOSIS & TREATMENT, 2022-2030 (USD MILLION)

TABLE 67 UK: HEART TUMOR MARKET, BY DIAGNOSIS, 2022-2030 (USD MILLION)

TABLE 68 UK: HEART TUMOR MARKET, BY TREATMENT, 2022-2030 (USD MILLION)

TABLE 69 UK: HEART TUMOR MARKET, BY TREATMENT, 2022-2030 (CYCLES)

TABLE 70 FRANCE: HEART TUMOR MARKET, BY TUMOR TYPE, 2022-2030 (USD MILLION)

TABLE 71 FRANCE: HEART TUMOR MARKET, BY TUMOR TYPE, 2022-2030 (CYCLES)

TABLE 72 FRANCE: HEART TUMOR MARKET, BY DIAGNOSIS & TREATMENT, 2022-2030 (USD MILLION)

TABLE 73 FRANCE: HEART TUMOR MARKET, BY DIAGNOSIS, 2022-2030 (USD MILLION)

TABLE 74 FRANCE: HEART TUMOR MARKET, BY TREATMENT, 2022-2030 (USD MILLION)

TABLE 75 FRANCE: HEART TUMOR MARKET, BY TREATMENT, 2022-2030 (CYCLES)

TABLE 76 ITALY: HEART TUMOR MARKET, BY TUMOR TYPE, 2022-2030 (USD MILLION)

TABLE 77 ITALY: HEART TUMOR MARKET, BY TUMOR TYPE, 2022-2030 (CYCLES)

TABLE 78 ITALY: HEART TUMOR MARKET, BY DIAGNOSIS & TREATMENT, 2022-2030 (USD MILLION)

TABLE 79 ITALY: HEART TUMOR MARKET, BY DIAGNOSIS, 2022-2030 (USD MILLION)

TABLE 80 ITALY: HEART TUMOR MARKET, BY TREATMENT, 2022-2030 (USD MILLION)

TABLE 81 ITALY: HEART TUMOR MARKET, BY TREATMENT, 2022-2030 (CYCLES)

TABLE 82 SPAIN: HEART TUMOR MARKET, BY TUMOR TYPE, 2022-2030 (USD MILLION)

TABLE 83 SPAIN: HEART TUMOR MARKET, BY TUMOR TYPE, 2022-2030 (CYCLES)

TABLE 84 SPAIN: HEART TUMOR MARKET, BY DIAGNOSIS & TREATMENT, 2022-2030 (USD MILLION)

TABLE 85 SPAIN: HEART TUMOR MARKET, BY DIAGNOSIS, 2022-2030 (USD MILLION)

TABLE 86 SPAIN: HEART TUMOR MARKET, BY TREATMENT, 2022-2030 (USD MILLION)

TABLE 87 SPAIN: HEART TUMOR MARKET, BY TREATMENT, 2022-2030 (CYCLES)

TABLE 88 REST OF EUROPE: HEART TUMOR MARKET, BY TUMOR TYPE, 2022-2030 (USD MILLION)

TABLE 89 REST OF EUROPE: HEART TUMOR MARKET, BY TUMOR TYPE, 2022-2030 (CYCLES)

TABLE 90 REST OF EUROPE: HEART TUMOR MARKET, BY DIAGNOSIS & TREATMENT, 2022-2030 (USD MILLION)

TABLE 91 REST OF EUROPE: HEART TUMOR MARKET, BY DIAGNOSIS, 2022-2030 (USD MILLION)

TABLE 92 REST OF EUROPE: HEART TUMOR MARKET, BY TREATMENT, 2022-2030 (USD MILLION)

TABLE 93 REST OF EUROPE: HEART TUMOR MARKET, BY TREATMENT, 2022-2030 (CYCLES)

TABLE 94 ASIA-PACIFIC: HEART TUMOR MARKET, BY COUNTRY, 2022-2030 (USD MILLION)

TABLE 95 ASIA-PACIFIC: HEART TUMOR MARKET, BY COUNTRY, 2022-2030 (CYCLES)

TABLE 96 ASIA-PACIFIC: HEART TUMOR MARKET, BY TUMOR TYPE, 2022-2030 (USD MILLION)

TABLE 97 ASIA-PACIFIC: HEART TUMOR MARKET, BY TUMOR TYPE, 2022-2030 (CYCLES)

TABLE 98 ASIA-PACIFIC: HEART TUMOR MARKET, BY DIAGNOSIS & TREATMENT, 2022-2030 (USD MILLION)

TABLE 99 ASIA-PACIFIC: HEART TUMOR MARKET, BY DIAGNOSIS, 2022-2030 (USD MILLION)

TABLE 100 ASIA-PACIFIC: HEART TUMOR MARKET, BY TREATMENT, 2022-2030 (USD MILLION)

TABLE 101 ASIA-PACIFIC: HEART TUMOR MARKET, BY TREATMENT, 2022-2030 (CYCLES)

TABLE 102 JAPAN: HEART TUMOR MARKET, BY TUMOR TYPE, 2022-2030 (USD MILLION)

TABLE 103 JAPAN: HEART TUMOR MARKET, BY TUMOR TYPE, 2022-2030 (CYCLES)

TABLE 104 JAPAN: HEART TUMOR MARKET, BY DIAGNOSIS & TREATMENT, 2022-2030 (USD MILLION)

TABLE 105 JAPAN: HEART TUMOR MARKET, BY DIAGNOSIS, 2022-2030 (USD MILLION)

TABLE 106 JAPAN: HEART TUMOR MARKET, BY TREATMENT, 2022-2030 (USD MILLION)

TABLE 107 JAPAN: HEART TUMOR MARKET, BY TREATMENT, 2022-2030 (CYCLES)

TABLE 108 CHINA: HEART TUMOR MARKET, BY TUMOR TYPE, 2022-2030 (USD MILLION)

TABLE 109 CHINA: HEART TUMOR MARKET, BY TUMOR TYPE, 2022-2030 (CYCLES)

TABLE 110 CHINA: HEART TUMOR MARKET, BY DIAGNOSIS & TREATMENT, 2022-2030 (USD MILLION)

TABLE 111 CHINA: HEART TUMOR MARKET, BY DIAGNOSIS, 2022-2030 (USD MILLION)

TABLE 112 CHINA: HEART TUMOR MARKET, BY TREATMENT, 2022-2030 (USD MILLION)

TABLE 113 CHINA: HEART TUMOR MARKET, BY TREATMENT, 2022-2030 (CYCLES)

TABLE 114 INDIA: HEART TUMOR MARKET, BY TUMOR TYPE, 2022-2030 (USD MILLION)

TABLE 115 INDIA: HEART TUMOR MARKET, BY TUMOR TYPE, 2022-2030 (CYCLES)

TABLE 116 INDIA: HEART TUMOR MARKET, BY DIAGNOSIS & TREATMENT, 2022-2030 (USD MILLION)

TABLE 117 INDIA: HEART TUMOR MARKET, BY DIAGNOSIS, 2022-2030 (USD MILLION)

TABLE 118 INDIA: HEART TUMOR MARKET, BY TREATMENT, 2022-2030 (USD MILLION)

TABLE 119 INDIA: HEART TUMOR MARKET, BY TREATMENT, 2022-2030 (CYCLES)

TABLE 120 AUSTRALIA: HEART TUMOR MARKET, BY TUMOR TYPE, 2022-2030 (USD MILLION)

TABLE 121 AUSTRALIA: HEART TUMOR MARKET, BY TUMOR TYPE, 2022-2030 (CYCLES)

TABLE 122 AUSTRALIA: HEART TUMOR MARKET, BY DIAGNOSIS & TREATMENT, 2022-2030 (USD MILLION)

TABLE 123 AUSTRALIA: HEART TUMOR MARKET, BY DIAGNOSIS, 2022-2030 (USD MILLION)

TABLE 124 AUSTRALIA: HEART TUMOR MARKET, BY TREATMENT, 2022-2030 (USD MILLION)

TABLE 125 AUSTRALIA: HEART TUMOR MARKET, BY TREATMENT, 2022-2030 (CYCLES)

TABLE 126 SOUTH KOREA: HEART TUMOR MARKET, BY TUMOR TYPE, 2022-2030 (USD MILLION)

TABLE 127 SOUTH KOREA: HEART TUMOR MARKET, BY TUMOR TYPE, 2022-2030 (CYCLES)

TABLE 128 SOUTH KOREA: HEART TUMOR MARKET, BY DIAGNOSIS & TREATMENT, 2022-2030 (USD MILLION)

TABLE 129 SOUTH KOREA: HEART TUMOR MARKET, BY DIAGNOSIS, 2022-2030 (USD MILLION)

TABLE 130 SOUTH KOREA: HEART TUMOR MARKET, BY TREATMENT, 2022-2030 (USD MILLION)

TABLE 131 SOUTH KOREA: HEART TUMOR MARKET, BY TREATMENT, 2022-2030 (CYCLES)

TABLE 132 REST OF ASIA-PACIFIC: HEART TUMOR MARKET, BY TUMOR TYPE, 2022-2030 (USD MILLION)

TABLE 133 REST OF ASIA-PACIFIC: HEART TUMOR MARKET, BY TUMOR TYPE, 2022-2030 (CYCLES)

TABLE 134 REST OF ASIA-PACIFIC: HEART TUMOR MARKET, BY DIAGNOSIS & TREATMENT, 2022-2030 (USD MILLION)

TABLE 135 REST OF ASIA-PACIFIC: HEART TUMOR MARKET, BY DIAGNOSIS, 2022-2030 (USD MILLION)

TABLE 136 REST OF ASIA-PACIFIC: HEART TUMOR MARKET, BY TREATMENT, 2022-2030 (USD MILLION)

TABLE 137 REST OF ASIA-PACIFIC: HEART TUMOR MARKET, BY TREATMENT, 2022-2030 (CYCLES)

TABLE 138 REST OF THE WORLD: HEART TUMOR MARKET, BY COUNTRY, 2022-2030 (USD MILLION)

TABLE 139 REST OF THE WORLD: HEART TUMOR MARKET, BY COUNTRY, 2022-2030 (CYCLES)

TABLE 140 REST OF THE WORLD: HEART TUMOR MARKET, BY TUMOR TYPE, 2022-2030 (USD MILLION)

TABLE 141 REST OF THE WORLD: HEART TUMOR MARKET, BY TUMOR TYPE, 2022-2030 (CYCLES)

TABLE 142 REST OF THE WORLD: HEART TUMOR MARKET, BY DIAGNOSIS & TREATMENT, 2022-2030 (USD MILLION)

TABLE 143 REST OF THE WORLD: HEART TUMOR MARKET, BY DIAGNOSIS, 2022-2030 (USD MILLION)

TABLE 144 REST OF THE WORLD: HEART TUMOR MARKET, BY TREATMENT, 2022-2030 (USD MILLION)

TABLE 145 REST OF THE WORLD: HEART TUMOR MARKET, BY TREATMENT, 2022-2030 (CYCLES)

TABLE 146 MIDDLE EAST: HEART TUMOR MARKET, BY TUMOR TYPE, 2022-2030 (USD MILLION)

TABLE 147 MIDDLE EAST: HEART TUMOR MARKET, BY TUMOR TYPE, 2022-2030 (CYCLES)

TABLE 148 MIDDLE EAST: HEART TUMOR MARKET, BY DIAGNOSIS & TREATMENT, 2022-2030 (USD MILLION)

TABLE 149 MIDDLE EAST: HEART TUMOR MARKET, BY DIAGNOSIS, 2022-2030 (USD MILLION)

TABLE 150 MIDDLE EAST: HEART TUMOR MARKET, BY TREATMENT, 2022-2030 (USD MILLION)

TABLE 151 MIDDLE EAST: HEART TUMOR MARKET, BY TREATMENT, 2022-2030 (CYCLES)

TABLE 152 AFRICA: HEART TUMOR MARKET, BY TUMOR TYPE, 2022-2030 (USD MILLION)

TABLE 153 AFRICA: HEART TUMOR MARKET, BY TUMOR TYPE, 2022-2030 (CYCLES)

TABLE 154 AFRICA: HEART TUMOR MARKET, BY DIAGNOSIS & TREATMENT, 2022-2030 (USD MILLION)

TABLE 155 AFRICA: HEART TUMOR MARKET, BY DIAGNOSIS, 2022-2030 (USD MILLION)

TABLE 156 AFRICA: HEART TUMOR MARKET, BY TREATMENT, 2022-2030 (USD MILLION)

TABLE 157 AFRICA: HEART TUMOR MARKET, BY TREATMENT, 2022-2030 (CYCLES)

TABLE 158 LATIN AMERICA: HEART TUMOR MARKET, BY TUMOR TYPE, 2022-2030 (USD MILLION)

TABLE 159 LATIN AMERICA: HEART TUMOR MARKET, BY TUMOR TYPE, 2022-2030 (CYCLES)

TABLE 160 LATIN AMERICA: HEART TUMOR MARKET, BY DIAGNOSIS & TREATMENT, 2022-2030 (USD MILLION)

TABLE 161 LATIN AMERICA: HEART TUMOR MARKET, BY DIAGNOSIS, 2022-2030 (USD MILLION)

TABLE 162 LATIN AMERICA: HEART TUMOR MARKET, BY TREATMENT, 2022-2030 (USD MILLION)

TABLE 163 LATIN AMERICA: HEART TUMOR MARKET, BY TREATMENT, 2022-2030 (CYCLES)

TABLE 164 MAJOR PLAYERS IN THE GLOBAL HEART TUMOR MARKET

TABLE 165 MOST ACTIVE PLAYER IN THE GLOBAL HEART TUMOR MARKET

TABLE 166 PRODUCT LAUNCH/ PRODUCT APPROVAL

TABLE 167 PARTERSHIP/AGREEMENT

TABLE 168 MERGER/ACQUISTION

TABLE 169 EXPANSION/INVESTMENT

TABLE 170 KONINKLIJKE PHILIPS N.V.: PRODUCTS OFFERED

TABLE 171 KONINKLIJKE PHILIPS N.V.: KEY DEVELOPMENTS

TABLE 172 FUJIFILM CORPORATION: PRODUCTS OFFERED

TABLE 173 FUJIFILM CORPORATION: KEY DEVELOPMENTS

TABLE 174 GE HEALTHCARE: PRODUCTS OFFERED

TABLE 175 GE HEALTHCARE: KEY DEVELOPMENTS

TABLE 176 SIEMENS: PRODUCTS OFFERED

TABLE 177 SIEMENS: KEY DEVELOPMENTS

TABLE 178 AMNEAL PHARMACEUTICALS LLC: PRODUCTS OFFERED

TABLE 179 SHIMADZU CORPORATION: PRODUCTS OFFERED

TABLE 180 SHIMADZU CORPORATION: KEY DEVELOPMENTS

TABLE 181 TOMTEC IMAGING SYSTEMS GMBH: PRODUCTS OFFERED

TABLE 182 TOSHIBA CORPORATION: PRODUCTS OFFERED

TABLE 183 BOSTON SCIENTIFIC CORPORATION: PRODUCTS OFFERED

TABLE 184 BOSTON SCIENTIFIC CORPORATION: KEY DEVELOPMENTS

TABLE 185 TERUMO CARDIOVASCULAR SYSTEMS CORPORATION: PRODUCTS OFFERED

LIST OF FIGURES

FIGURE 1 MARKET SYNOPSIS

FIGURE 2 GLOBAL HEART TUMOR MARKET STRUCTURE

FIGURE 3 BOTTOM-UP AND TOP-DOWN APPROACHES

FIGURE 4 MARKET DYNAMICS: ANALYSIS OF THE GLOBAL HEART TUMOR MARKET

FIGURE 5 DRIVER IMPACT ANALYSIS

FIGURE 6 RESTRAINT IMPACT ANALYSIS

FIGURE 7 VALUE CHAIN ANALYSIS: GLOBAL HEART TUMOR MARKET

FIGURE 8 PORTER'S FIVE FORCES ANALYSIS: GLOBAL HEART TUMOR MARKET

FIGURE 9 GLOBAL: HEART TUMOR MARKET, BY TUMOR TYPE, 2021 & 2030 (USD MILLION)

FIGURE 10 GLOBAL: HEART TUMOR MARKET, BY TUMOR TYPE, 2021 & 2030 (CYCLES)

FIGURE 11 GLOBAL: HEART TUMOR MARKET, BY DIAGNOSIS & TREATMENT, 2021 & 2030 (USD MILLION)

FIGURE 12 GLOBAL: HEART TUMOR MARKET, BY TREAMENT, 2021 & 2030 (CYCLES)

FIGURE 13 GLOBAL HEART TUMOR MARKET, BY REGION 2021 & 2030 (USD MILLION)

FIGURE 14 GLOBAL HEART TUMOR MARKET SHARE (%), BY REGION, 2021

FIGURE 15 NORTH AMERICA: HEART TUMOR MARKET SHARE (%), BY COUNTRY 2021

FIGURE 16 EUROPE: HEART TUMOR MARKET SHARE (%), BY COUNTRY 2021

FIGURE 17 ASIA-PACIFIC: HEART TUMOR MARKET SHARE, BY COUNTRY, 2021 (%)

FIGURE 18 REST OF THE WORLD: HEART TUMOR MARKET SHARE (%), BY COUNTRY, 2021

FIGURE 19 BENCHMARKING OF MAJOR COMPETITORS

FIGURE 20 MAJOR STRATEGY ADOPTED BY KEY PLAYERS IN THE GLOBAL HEART TUMOR MARKET

FIGURE 21 GLOBAL HEART TUMOR MARKET: COMPETITIVE LANDSCAPE

FIGURE 22 SALES 2021

FIGURE 23 R&D EXPENDITURE, 2021

FIGURE 24 KONINKLIJKE PHILIPS N.V.: FINANCIAL OVERVIEW SNAPSHOT

FIGURE 25 KONINKLIJKE PHILIPS N.V.: SWOT ANALYSIS

FIGURE 26 FUJIFILM CORPORATION: FINANCIAL OVERVIEW SNAPSHOT

FIGURE 27 FUJIFILM CORPORATION: SWOT ANALYSIS

FIGURE 28 GE HEALTHCARE: FINANCIAL OVERVIEW SNAPSHOT

FIGURE 29 GE HEALTHCARE: SWOT ANALYSIS

FIGURE 30 SIEMENS: FINANCIAL OVERVIEW

FIGURE 31 AMNEAL PHARMACEUTICALS LLC: FINANCIAL OVERVIEW SNAPSHOT

FIGURE 32 SHIMADZU CORPORATION: FINANCIAL OVERVIEW SNAPSHOT

FIGURE 33 SHIMADZU CORPORATION: SWOT ANALYSIS

FIGURE 34 TOSHIBA CORPORATION: FINANCIAL OVERVIEW SNAPSHOT

FIGURE 35 TOSHIBA CORPORATION: SWOT ANALYSIS

FIGURE 36 BOSTON SCIENTIFIC CORPORATION: FINANCIAL OVERVIEW SNAPSHOT

FIGURE 37 TERUMO CARDIOVASCULAR SYSTEMS CORPORATION: FINANCIAL OVERVIEW SNAPSHOT

Purchase Option
Single User $ 4,950
Multiuser License $ 5,950
Enterprise User $ 7,250
Compare Licenses
Tailored for You
  • Dedicated Research on any specifics segment or region.
  • Focused Research on specific players in the market.
  • Custom Report based only on your requirements.
  • Flexibility to add or subtract any chapter in the study.
  • Historic data from 2014 and forecasts outlook till 2040.
  • Flexibility of providing data/insights in formats (PDF, PPT, Excel).
  • Provide cross segmentation in applicable scenario/markets.